Literature DB >> 31519689

MUC1-C Activates the NuRD Complex to Drive Dedifferentiation of Triple-Negative Breast Cancer Cells.

Tsuyoshi Hata1, Hasan Rajabi1, Hidekazu Takahashi1, Yota Yasumizu1, Wei Li1, Caining Jin1, Mark D Long2, Qiang Hu2, Song Liu2, Atsushi Fushimi1, Nami Yamashita1, Ling Kui1, Deli Hong1, Masaaki Yamamoto1, Masaaki Miyo1, Masayuki Hiraki1, Takahiro Maeda1, Yozo Suzuki1, Mehmet K Samur1, Donald Kufe3.   

Abstract

The NuRD chromatin remodeling and deacetylation complex, which includes MTA1, MBD3, CHD4, and HDAC1 among other components, is of importance for development and cancer progression. The oncogenic mucin 1 (MUC1) C-terminal subunit (MUC1-C) protein activates EZH2 and BMI1 in the epigenetic reprogramming of triple-negative breast cancer (TNBC). However, there is no known link between MUC1-C and chromatin remodeling complexes. Here, we showed that MUC1-C binds directly to the MYC HLH-LZ domain and identified a previously unrecognized MUC1-C→MYC pathway that regulates the NuRD complex. MUC1-C/MYC complexes selectively activated the MTA1 and MBD3 genes and posttranscriptionally induced CHD4 expression in basal- but not luminal-type BC cells. In turn, MUC1-C formed complexes with these NuRD components on the ESR1 promoter. Downregulating MUC1-C decreased MTA1/MBD3/CHD4/HDAC1 occupancy and increased H3K27 acetylation on the ESR1 promoter, with induction of ESR1 expression and downstream estrogen response pathways. Targeting MUC1-C and these NuRD components also induced expression of FOXA1, GATA3, and other markers associated with the luminal phenotype. These findings support a model in which MUC1-C activates the NuRD complex to drive dedifferentiation and reprogramming of TNBC cells. SIGNIFICANCE: MUC1-C directly interacts with MYC to activate the NuRD complex, mediating regulation of the estrogen receptor in triple-negative breast cancer cells. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31519689      PMCID: PMC6881519          DOI: 10.1158/0008-5472.CAN-19-1034

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Authors:  Jake E Delmore; Ghayas C Issa; Madeleine E Lemieux; Peter B Rahl; Junwei Shi; Hannah M Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M Paranal; Jun Qi; Marta Chesi; Anna C Schinzel; Michael R McKeown; Timothy P Heffernan; Christopher R Vakoc; P Leif Bergsagel; Irene M Ghobrial; Paul G Richardson; Richard A Young; William C Hahn; Kenneth C Anderson; Andrew L Kung; James E Bradner; Constantine S Mitsiades
Journal:  Cell       Date:  2011-09-01       Impact factor: 41.582

2.  Differential regulation of estrogen receptor α expression in breast cancer cells by metastasis-associated protein 1.

Authors:  Hyun-Jin Kang; Min-Ho Lee; Hae-Lim Kang; Sung-Hye Kim; Jung-Ranh Ahn; Hyelin Na; Tae-Young Na; Yo Na Kim; Je Kyung Seong; Mi-Ock Lee
Journal:  Cancer Res       Date:  2014-01-10       Impact factor: 12.701

Review 3.  Role of MTA1 in cancer progression and metastasis.

Authors:  Nirmalya Sen; Bin Gui; Rakesh Kumar
Journal:  Cancer Metastasis Rev       Date:  2014-12       Impact factor: 9.264

4.  Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer.

Authors:  Tsuyoshi Hata; Hasan Rajabi; Masaaki Yamamoto; Caining Jin; Rehan Ahmad; Yan Zhang; Ling Kui; Wei Li; Yota Yasumizu; Deli Hong; Masaaki Miyo; Masayuki Hiraki; Takahiro Maeda; Yozo Suzuki; Hidekazu Takahashi; Mehmet Samur; Donald Kufe
Journal:  Mol Cancer Ther       Date:  2019-07-15       Impact factor: 6.261

5.  Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation.

Authors:  Tsung-Cheng Chang; Lauren R Zeitels; Hun-Way Hwang; Raghu R Chivukula; Erik A Wentzel; Michael Dews; Jason Jung; Ping Gao; Chi V Dang; Michael A Beer; Andrei Thomas-Tikhonenko; Joshua T Mendell
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-11       Impact factor: 11.205

Review 6.  Mucins in cancer: function, prognosis and therapy.

Authors:  Donald W Kufe
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

7.  Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1.

Authors:  Young-Gun Yoo; Gu Kong; Mi-Ock Lee
Journal:  EMBO J       Date:  2006-03-02       Impact factor: 11.598

8.  MUC1-C activates EZH2 expression and function in human cancer cells.

Authors:  Hasan Rajabi; Masayuki Hiraki; Ashujit Tagde; Maroof Alam; Audrey Bouillez; Camilla L Christensen; Mehmet Samur; Kwok-Kin Wong; Donald Kufe
Journal:  Sci Rep       Date:  2017-08-07       Impact factor: 4.379

9.  A novel FOXA1/ESR1 interacting pathway: A study of Oncomine™ breast cancer microarrays.

Authors:  Sanjib Chaudhary; B Madhu Krishna; Sandip K Mishra
Journal:  Oncol Lett       Date:  2017-06-07       Impact factor: 2.967

10.  Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target.

Authors:  Deepak Raina; Praveen Agarwal; James Lee; Ajit Bharti; C James McKnight; Pankaj Sharma; Surender Kharbanda; Donald Kufe
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

View more
  23 in total

Review 1.  Intrinsic and Extrinsic Factors Governing the Transcriptional Regulation of ESR1.

Authors:  David K Lung; Rebecca M Reese; Elaine T Alarid
Journal:  Horm Cancer       Date:  2020-06-26       Impact factor: 3.869

Review 2.  MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment.

Authors:  Donald W Kufe
Journal:  Carcinogenesis       Date:  2020-09-24       Impact factor: 4.944

Review 3.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

4.  MUC1-C drives stemness in progression of colitis to colorectal cancer.

Authors:  Wei Li; Ning Zhang; Caining Jin; Mark D Long; Hasan Rajabi; Yota Yasumizu; Atsushi Fushimi; Nami Yamashita; Masayuki Hagiwara; Rongbin Zheng; Jin Wang; Ling Kui; Harpal Singh; Surender Kharbanda; Qiang Hu; Song Liu; Donald Kufe
Journal:  JCI Insight       Date:  2020-06-18

5.  MUC1-C Dictates JUN and BAF-Mediated Chromatin Remodeling at Enhancer Signatures in Cancer Stem Cells.

Authors:  Atrayee Bhattacharya; Atsushi Fushimi; Nami Yamashita; Masayuki Hagiwara; Yoshihiro Morimoto; Hasan Rajabi; Mark D Long; Maha Abdulla; Rehan Ahmad; Kelly Street; Song Liu; Tao Liu; Donald Kufe
Journal:  Mol Cancer Res       Date:  2022-04-01       Impact factor: 5.852

6.  Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non-neuroendocrine Small Cell Lung Cancer.

Authors:  Atsushi Fushimi; Yoshihiro Morimoto; Satoshi Ishikawa; Nami Yamashita; Atrayee Bhattacharya; Tatsuaki Daimon; Hasan Rajabi; Caining Jin; Masayuki Hagiwara; Yota Yasumizu; Zhou Luan; Wenhao Suo; Kwok-Kin Wong; Henry Withers; Song Liu; Mark D Long; Donald Kufe
Journal:  Mol Cancer Res       Date:  2022-09-02       Impact factor: 6.333

Review 7.  Recent Insight on Regulations of FBXW7 and Its Role in Immunotherapy.

Authors:  Liangliang Xing; Leidi Xu; Yong Zhang; Yinggang Che; Min Wang; Yongxiang Shao; Dan Qiu; Honglian Yu; Feng Zhao; Jian Zhang
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

8.  MUC1-C Activates the BAF (mSWI/SNF) Complex in Prostate Cancer Stem Cells.

Authors:  Masayuki Hagiwara; Yota Yasumizu; Nami Yamashita; Hasan Rajabi; Atsushi Fushimi; Mark D Long; Wei Li; Atrayee Bhattacharya; Rehan Ahmad; Mototsugu Oya; Song Liu; Donald Kufe
Journal:  Cancer Res       Date:  2020-12-15       Impact factor: 13.312

Review 9.  Sophisticated Conversations between Chromatin and Chromatin Remodelers, and Dissonances in Cancer.

Authors:  Cedric R Clapier
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

10.  circPRRC2A promotes angiogenesis and metastasis through epithelial-mesenchymal transition and upregulates TRPM3 in renal cell carcinoma.

Authors:  Wei Li; Feng-Qiang Yang; Chen-Min Sun; Jian-Hua Huang; Hai-Min Zhang; Xue Li; Guang-Chun Wang; Ning Zhang; Jian-Ping Che; Wen-Tao Zhang; Yang Yan; Xu-Dong Yao; Bo Peng; Jun-Hua Zheng; Min Liu
Journal:  Theranostics       Date:  2020-03-15       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.